Acutaas Chemicals Ltd (ACUTAAS)
₹4,003.60
Mkt cap
₹32,778 Cr
P/E ratio
74.60
P/B
17.64
Div yield
0.06%
ROE
24.00%
ROCE
31.60%
EPS (TTM)
₹53.67
Book value
₹227
52W range
1,570–4,032
Sector
Healthcare
Price history
Previous close
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals. [1]
NSE ACUTAASBSE 543349
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−0.71% from high₹4,004
₹1,570+155.01% from low₹4,032
Current
₹4,003.60
Prev close
₹3,976.70
Day
+0.68%
Price performance
1D
+0.78%
1W
+27.73%
1M
+21.29%
3M
+23.93%
6M
+60.15%
1Y
+130.30%
YTD
+128.87%
Financials
Revenue, profit & margin
P/E ratio
74.6×
ACUTAAS is 119% above the sector median of 34.0×
ACUTAAS74.6×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 172 | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 | 437 | |
| Expenses | 148 | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 | 243 | 249 | 217 | 261 | |
| Operating Profit | 25 | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 | 151 | 184 | 113 | 176 | |
| OPM % | 14% | 16% | 19% | 17% | 20% | 25% | 28% | 25% | 31% | 38% | 42% | 34% | 40% | |
| Other Income | -30 | 3 | 1 | 1 | 8 | 2 | 6 | 16 | 10 | 5 | 11 | 2 | 5 | |
| Interest | 1 | 3 | 2 | 4 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 8 | 10 | 10 | 10 | 13 | |
| Profit before tax | -10 | 24 | 37 | 20 | 50 | 63 | 83 | 58 | 96 | 145 | 184 | 104 | 167 | |
| Tax % | 71% | 25% | 31% | 26% | 25% | 28% | 24% | 24% | 25% | 27% | 27% | 28% | 26% | |
| Net Profit | -17 | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 | 123 | |
| EPS in Rs | -2.55 | 2.27 | 3.41 | 1.71 | 4.56 | 5.49 | 7.63 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 | 15.29 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.05% · closed higher next day 13 of last 20
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 13 Feb '24 | 12 May '24◦ | 13 Aug '24 | 29 Oct '24◦ | 29 Jan '25◦ | 2 May '25◦ | 30 Jul '25 | 17 Oct '25 | 28 Jan '26 | 30 Apr '26 | 24 Jul '26 | 27 Oct '26 |
| Earnings day | +4.80% | +2.00% | −3.79% | +5.43% | +4.45% | +3.47% | +4.56% | +6.02% | +7.78% | +3.66% | −5.77% | −2.20% |
| +1 day | +4.78% | +0.64% | −4.79% | +8.63% | +5.63% | −2.67% | +13.73% | +13.53% | +11.93% | +6.95% | −2.64% | +4.83% |
| +5 days | +4.91% | +3.10% | +2.79% | +13.41% | +16.32% | +1.91% | +12.72% | +10.38% | +15.09% | +9.27% | −10.24% | — |
| +15 days | +10.95% | +0.31% | +9.01% | +17.85% | −2.23% | +2.53% | +20.01% | +9.86% | +24.03% | +17.93% | −6.46% | — |
| +30 days | +4.30% | +8.65% | +29.47% | +15.95% | −3.35% | −5.87% | +23.56% | +11.72% | +26.60% | +23.75% | −8.40% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202632.66%Promoter
Promoters32.66%
FIIs22.61%1.00
DIIs19.40%0.15
Public25.31%0.85
Government0.01%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Acutaas Chemical | ₹4,003.60 | 74.64 | 32,778 | 0.06% | 123 | +73.27% | 437 | +42.69% | 31.56% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports6
Concall transcripts55
PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026PPTApr 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptOct 2025PPTOct 2025RECOct 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024
Credit ratings3
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Oct - Newspaper Publication of the Unaudited Financial Results for the second quarter ended September 30, 2026 as attached.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 27 Oct - Earnings call recording held on October 27, 2026 is available on Acutaas Chemicals’ website.Announcement under Regulation 30 (LODR)-Investor Presentation 27 Oct - Investor Presentation on financial results for the second quarter and half year ended as on September 30, 2026 is enclosed.Announcement under Regulation 30 (LODR)-Press Release / Media Release 27 Oct - Q2 FY27 revenue rose 42.7% to ₹4,369mn; South Korea facility inaugurated, FY27 guidance raised.Unaudited Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended September 30, 2026 27 Oct - Acutaas reported Q2/H1 FY2026 results; Indichem semiconductor plant inaugurated on August 28, 2026, under trial runs.